The Importance of More Thoughtful Treatment Strategies in High-Risk CLL

Video

“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE®.

When it comes to treating patients with chronic lymphocytic leukemia (CLL), oncologists have a number of treatment options to create a plan that limits the time on any given therapy and reduces the toxicities a patient might face. But for high-risk patients, more work must be done to create effective treatment strategies, according to Dr. Mazyar Shadman of the Seattle Cancer Care Alliance.

In a recent interview with CURE®, Shadman explained how his approach to treating CLL is more strategic than simply relying on one standard of therapy. “If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” said Shadman.

Transcription:

The way I look at CLL, these days, is we either have what I call standard-risk CLL - these are patients who don't have high-risk features - and then we have high-risk CLL. And those are patients who either have a high-risk molecular marker or they may not have that marker, but their disease progressed on some of our good drugs. So that would be a high-risk disease, right? So, if you have somebody whose disease came back after one or two lines of the best treatment, that's a difficulty.

So, for standard-risk CLL, we're focusing on making treatment time-limited and less toxic. I kind of mentioned this earlier. For high-risk, there's much more to do and we still need treatment strategies that are more effective. As I mentioned earlier, one of the things that we have been doing here and in some (other) major centers really, (is that we) have a program that doesn't focus on a treatment modality but focuses on a strategy. So, if I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working.

I guess my point is, as a center that has access to novel agents, chemotherapy, rarely, but you know, everybody has it - cellular therapy, it could be bispecific therapy, is more important. And if you're very active with CAR T-cell therapy, and that, if needed for selected patients, allogeneic stem cell transplant, I think that it's very critical to know how to sequence these treatments. What is the right time to jump from one treatment to the other.

And again, I repeat, this is not for everybody. The majority of patients these days are fortunate, and they fit in the standard category. And we just have work to do there, but a different type of work. But for high-risk patients, I think it's very important to have a strategy and not just go on treatment and say ‘Oh, it's working. I'm going to forget about CLL until I need to.’ — no.

Sometimes the time to move on to another treatment is when you're responding to treatment and everything is fine. So that's why kind of having a plan for your disease and having a more general big picture vision is very important. And that's my main advice for patients with high-risk disease.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE